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LEUKOCYTOSIS and thrombocytopenia occur during
cardiopulmonary bypass (CPB) with extracorpor-
eal circulation (ECC). Elevated circulating concen-
trations of macrophage colony-stimulating factor
(M-CSF) are reported during thrombocytopenia
and leukopenia of different origins. We have
assessed M-CSF concentrations in 40 patients
undergoing CPB with ECC. Plasma M-CSF concen-
trations were stable during ECC and increased at
the 6th (7.3 + 0.7IU/tg protein) and 24th
(8.6 + 0.8 IU/og protein) postoperative hour com-
pared with pre-ECC values (4.9 + 0.5 IU/tg pro-
tein). A deep thrombocytopenia was found during
ECC and until the 24th postoperative hour. A drop
of leukocyte counts was found during ECC fol-
lowed by an increase after ECC weaning. While
no correlation was found between M-CSF concen-
trations and the leukocyte counts, M-CSF values
were positively correlated with platelet counts
only before and during ECC. Thus, M-CSF is not
implicated in the thrombocytopenia and the
leukopenia generated during CPB with ECC. How-
ever the elevated levels of M-CSFa few hours after
the end of ECC might play a role in the inflam-
matory process often observed after CPB.
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Introduction
Cardiopulmonary bypass (CPB) with extracor-
poreal circulation (ECC) results in major haema-
tological changes including leukocytosis and
thrombocytopenia. The release of several in-
flammator compounds including cytokines,
eicosanoids, platelet-activating factor (PAF), and
activation of the coagulation and the comple-
ment cascade are suspected to play a role in
these haematological disorders and in the patho-
genesis of the inflammatory syndrome observed
after CPB.2-6
Monocte/macrophage activation accompa-
nies CPB. Macrophage colony-stimulating factor
(M-CSF), also known as CSF-1, is a major
regulator of the production as well as functional
state of cells of the mononuclear-phagocytic
lineage.8’9 M-CSF is produced by numerous cell
types such as endothelial cells, monocytes/
macrophages, T- and B-cells spontaneously or
after induction.
8-1 M-CSF acts on mature mono-
cytes/macrophages, stimulating production of
tumour necrosis factor (TNF), interferon, inter-
leukin-6 (IL6), prostaglandins and CSFs11-13.
Some reports have highlighted the role of M-
CSF in the pathogenesis of thrombocytopenia
and leukopenia of various origins.
14-16 The
purpose of this study was to assess plasma M-
CSF concentrations during and after cardiac
surgery with ECC. We also investigated the
relationship between platelet and leukocyte
counts and M-CSF levels during and after CPB.
Patients and Methods
After ethical committee approval, 40 patients
scheduled to undergo coronary artery bypass
graft were included in this prospective study.
All the patients gave written informed consent.
Anaesthesia
All patients had a preoperative ejection fraction
above 40%. Upon arrival on operating room, all
patients received their usual oral cardiac medi-
cation, flunitrazepam (2mg) and morphine
(lOmg) intramuscularly. Anaesthesia was in-
duced and maintained with titrated doses of
fentanyl and flunitrazepam. Muscular relaxation
was achieved with pancuronium (0.1 mg/kg).
Bubble or membrane oxygenators were used
according to the planed number of graft and
surgical difficulties. The blood was harvested
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from surgical field and from the cell saver at the microtitre plates. Standard dilutions of M-CSF
end of ECC and reinfused to all patients. All (400 to 6 international units per ml (IU/ml) of
patients (except two with uneventful surgery) human M-CSE international standard, NIBSC,
received high doses aprotinin. All the patients Potters Bar, UK) and samples were transferred
were managed by the same surgical anaesthetic into wells and incubated overnight at 4C.
team. Plates were washed and anti-M-CSF-biotin con-
jugate was added to all wells and incubated
Blood sampling and haematologic overnight at 4C. Plates were washed and
measurements avidine phosphatase (1 Ig/ml) was added to
wells and incubated for 1 h at 37C. The
Blood samples were collected from the radial revelation was performed with para-nitrophe-
artery catheter at the following times: before nyl-phosphate disodium (4 g/ml) for 15 min at
vascular cannulation and after opening the 37C. The reaction was blocked by addition of
chest (To), during ECC just before (T1) and after 50 bl of NaOH lON to the wells. Colour
cross-clamp release (T2), after weaning from development was measured at OD 405 nm. M-
ECC (T3), at the 6th (T4) and 24th post- CSF levels in samples were calculated with
operative hour (T5) (Fig. 1). Two ml of blood respect to the calibration curve obtained with
were placed in EDTA then centrifuged to obtain standard M-CSE The sensitivity of the assay
plasma which was stored at -80C until assay, enables detection of plasma M-CSF levels as low
Plasma samples were also collected from 36 as 10 IU/ml. Plasma M-CSF concentrations were
healthy individuals to assess plasma M-CSF expressed either as IU/ml for controls and for
concentrations in controls. Platelet and leuko- patients before surgery or as IU per microgram
cyte counts were determined in the radial artery of protein content (IU/pg) to exclude the influ-
blood at To, T, T, T4 and T5. ence of haemodilution for operated patients.
Haematological complications were biologic- The proteinaemia was determined at each time
ally determined at T3, T4 and T5 as follows: APTT of blood sampling by the BCA Protein Assay
values above 1.5, fibrinogen levels < 1 g/l, Reagent (Pierce, Rockford, IL).
factor V levels < 30%, and platelet count
< 70000 elements/mm. Clinical bleeding was Statistical analysis considered when blood loss reached values
above 100 ml/h. Haematological complications Results are expressed as mean 4- SEM. Statistical
were graded from 0 (absence) to 3 [biological analysis was performed by Kruskal Wallis analy-
trouble and significant bleeding leading (grade sis and Mann-Whitney U-test. A p < 0.05 was
3) or not (grade 2) to reoperation]. Grade 1 considered significant. Statistical analysis was
haematological complications were assumed performed using the statistics package ’stat-
when biological abnormalities were present graphic’. Correlations between M-CSF levels and
without clinical bleeding, platelet or leukocyte counts were calculated by
linear regression analysis.
M-CSF assay
Results M-CSF production was determined by a self-
made sandwich EIA procedure previously The demographic data of patients are shown in
described.
,18 Briefly, polyclonal anti-human M- Table 1. Plasma M-CSF concentrations of coron-
CSF immunoglobulins were coated on 96-well ary patients before ECC (223.7 4- 20.6 IU/ml,
Cannulation Cross clamp release
Induction 6 hr 24 hr
TO T1 T2T3 T4 T5
Post ECC
n 40) were not statistically (p > 0.05, Mann-
Whitney U-test) different compared
with healthy individuals (198.3 -+- 17.4 IU/ml,
n 36).
A significant (p < 0.01) drop in platelet and
leukocyte counts was observed in the radial
blood during ECC (Fig. 2). Platelet counts
remained low at the 6th and 24th postoperative
hour. By contrast leukocyte counts increased
significantly (p < 0.01) after weaning of ECC
FIG. 1. Blood sampling chronology. To: before vascular and at the 6th and 24th postoperative hour. As
cannulation and after opening the chest; TI: during ECC just shown in Fig. 2, plasma M-CSF concentrations
before cross-clamp release; T2" during ECC after cross-
clamp release; T3: after weaning from ECC; T4: the 6th were stable during ECC. Elevated levels (p <
postoperative hour; T5: the 24th postoperative hour. 0.01, Mann-Whitney U-test) of plasma M-CSF
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Table 1. Demographic data (mean 4- SEM)
Patients
(n- 40)
Age (years 67 4-
Weight (kg) 74 4- 2
Body surface area (m2) 1.84 4- 0.03
Ejection fraction (%) 58.6 4- 2.7 (n- 33)
Preoperative left ventricle diastolic 16.1 4- 1.6 (n- 36)
pressure (mmHg)
Number of grafts 3.0 4- 0.1
ECC duration 104 4- 6
Heparin doses (mg) 357 4- 11
Protamine doses (mg) 267 4- 9
Peroperative blood loss (ml) 603 4- 47
+ M-CSF (IU/ml/ug protein) Platelets (G/mm3)
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FIG. 2. Plasma M-CSF concentrations (O), platelet ((C)) and
leukocyte (I-I) counts during and after CPB. Platelet and
leukocyte counts are expressed in g/ml. M-CSF concentra-
tions are expressed in IU/ml/#g protein. Mean 4-SEM.
* p < 0.01 compared with To (Mann-Whitney U-test).
were found at the 6th (7.3 +0.7IU/ml/btg
protein) and 24th (8.6 -q- 0.8 IU/ml/gg protein)
postoperative hour compared with To (4.9-+-
0.5 IU/ml/pg protein).
A positive correlation was observed before
(To) and during ECC (T1) between platelet
counts and M-CSF concentrations (Table 2).
After cross-clamp release no correlation was
found between platelet counts and M-CSF con-
centrations. No correlation was found between
M-CSF concentrations and leukocyte counts at
any blood sampling time (Table 2).
No difference was documented between M-
CSF concentrations according to the grade of
haematological complications at T3, T4 and T5
(Fig. 3).
Discussion
This study shows that plasma M-CSF concentra-
tions are stable during ECC and increase at the
6th and 24th postoperative hour compared with
pre-ECC values. While lipidic mediators are
produced chiefly during ECC,7’8 elevated cyto-
kine concentrations are often found after few
hours.5’6’1 The time-course of M-CSF concentra-
tions during cardiac surgery fits well with those
of the other cytokines so far assessed. We may
speculate that the monocytes, lymphocytes, and
polymorphonuclear neutrophils ’primed’ by
CPB might be implicated in these elevated M-
CSF concentrations. However a lowering M-CSF
degradation might also explain our results. M-
CSF receptors is almost totally cleared from the
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FIG. 3. Plasma M-CSF after ECC (T3), at the 6th (T4) and 24th
(T5) postoperative hour in relation to the grade of haemato-
logical complication. Grade 0: no trouble; Grade 1: haema-
tological complication without clinical bleeding; Grade 2:
haematological complication with bleeding; Grade 3: hae-
matological complication with bleeding leading to reopera-
tion. M-CSF concentrations are expressed in IU/ml/Fg
protein. (n): number of patients.
Table2. Correlations between plasma M-CSF levels and platelet and leukocyte
counts during and after CPB. (n): number of patients
Time of blood sampling
To (n= 32) T1 (n= 32) T3 (n= 31) T4 (n- 33) T5 (n= 33)
Platelets r 0.39 r- 0..39 r 0.29 r-- 0.02 r- -0.04
p- 0.020 p- 0.022 p- 0.099 p 0.88 p- 0.81
Leukocytes r- 0.21 r- 0.24 r -0.15 r -0.12 r- 0.04
p- 0.22 p- 0.17 p-- 0.41 p 0.46 p- 0.78
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circulation by specific M-CSF receptors on
hepatic and splenic macrophages.11’12 A down-
regulation of M-CSF receptors at the surface of
macrophages has been reported in response to
inflammatory mediators and cytokines. Such a
phenomenon might also explain the elevated M-
CSF levels after CPB. The production of M-CSF
by peripheral blood leukocytes of patients
undergoing CPB with ECC deserves now to be
assessed.
M-CSF is suspected to play a role in the fall of
platelet counts during pregnancy,
14 and in pa-
tients with immune thrombocytopenic
purpura.
15 In this study M-CSF levels are stable
during ECC. While M-CSF levels are positively
correlated with platelet counts at the beginning
of ECC, no correlation is found with leukocyte
counts. Thus, M-CSF is not implicated in the
thrombocytopenia and the leukopenia which
occur at the beginning of ECC. Various media-
tors released during coronary reflow amplify
vascular cell margination and may participate to
vascular obstruction and to the no-reflow phe-
nomenon7 Immediately after ECC, plasma M-
CSF concentrations are similar to pre-ECC
values denying the involvement of M-CSF in the
haematologic changes generated during the
coronary reflow. After ECC the increase of
leukocyte counts occurs before the increase of
M-CSF concentration denying its role in the
post-ECC leukocytosis. In addition no difference
could be documented between M-CSF concen-
trations after ECC according to the grade of
haematological complications.
The concept that there is a marked synergy
between the effects of the various mediators
released during cardiac surgery is now widely
accepted.
2 A combination of small amounts of
them may be more active than a large release of
one by itself. M-CSF might play a role in the
inflammatory process observed after cardiac
surgery since the key cells of the inflammatory
response to CPB (i.e. monocytes, polymorpho-
nuclear neutrophils and lymphocytes) produce
M-CSF in response to cytokines and produce
cytokines in response to M-CSE8-13 In addition
elevated circulating amounts of granulocyte-CSF
(G-CSF) have been recently found after cardiac
surgery,
2 strengthening that the involvement of
growth factors after CPB deserves further eva-
luations.
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